The Role of Endothelial Dysfunction in Idiopathic Pulmonary Fibrosis: A Pathway to Novel Therapeutic Approaches


Idiopathic Pulmonary Fibrosis (IPF) is a debilitating lung disease characterized by progressive fibrosis of lung tissue, leading to impaired gas exchange, respiratory failure, and a dismal prognosis. It is a disease with increasing prevalence and limited therapeutic options, making it a significant challenge for both patients and healthcare professionals. IPF is thought to result from repeated injuries to the alveolar epithelium in genetically susceptible individuals, leading to aberrant activity of mesenchymal cell populations and the production of extracellular matrix (ECM) components. This process results in interstitial fibrosis, alveolar collapse, and a loss of effective lung tissue. The disease’s poor prognosis is reflected in a median survival of only 3 to 4 years, although antifibrotic therapies like pirfenidone and nintedanib have shown promise in slowing disease progression. The role of the pulmonary vasculature in IPF has garnered increasing attention. Research has indicated that endothelial cells (ECs) may play a more significant role than previously thought, moving beyond being mere bystander cells. These ECs can secrete profibrotic mediators and transdifferentiate into pathogenic myofibroblasts, indicating their active participation in IPF pathogenesis.

Vascular Smooth Muscle Cells (VSMCs) have also come under scrutiny. Abnormal proliferation and distribution of VSMCs have been observed in IPF tissue. TGF-β and PDGF, released in response to lung injury, stimulate VSMC proliferation, contributing to vascular remodeling and pulmonary hypertension (PH). VSMCs isolated from IPF patients show hyperproliferation and increased collagen production, which can be attenuated by the antifibrotic drug pirfenidone.

The latest research published in the peer-reviewed Journal Clinical Investigation by Dr. James May, Professor Jane Mitchell, and Professor Gisli Jenkins from Imperial College London sheds new light on the role of endothelial dysfunction in the pathogenesis of IPF and explores potential novel therapeutic avenues. The study highlights signaling crosstalk between ECs, VSMCs, and fibroblasts driven by TGF-β1 overexpression, resulting in EC apoptosis and VSMC activation and proliferation. This interaction is influenced by defective bone morphogenetic protein receptor 2 (BMPR2) signaling, linking IPF to pulmonary arterial hypertension.

Pericytes, mesenchymal cells closely related to fibroblasts, are also implicated in IPF. These cells, which interact extensively with ECs, have been shown to contribute significantly to the myofibroblast pool in pulmonary fibrosis. Disruption in the Wnt signaling pathway in both ECs and pericytes plays a role in their profibrotic transformation. The alveolar capillary basement membrane, a critical scaffold structure, supports normal alveolar repair. Loss of basement membrane integrity allows direct interaction between alveolar epithelial and mesenchymal cells, promoting TGF-β activation and myofibroblast activation. Abnormal collagen IV composition in the basement membrane limits myofibroblast migration and promotes their survival, contributing to fibroblastic foci and aberrant angiogenesis.

The authors discussed endothelial dysfunction  and that it is emerging as a crucial player in the pathogenesis of IPF. Research has revealed several pathways involving endothelial cells that contribute to fibrosis and vascular remodeling in IPF. They also described the role of Nitric oxide (NO) generated by eNOS in vascular ECs plays a vital role in regulating vascular tone, endothelial permeability, and platelet aggregation. Evidence suggests that NO is protective against fibrosis, but its role in IPF is complex. The NO pathway, particularly the NO/cGMP pathway, has been targeted in clinical trials, with mixed results. They also  reported the role of Endothelin which is a potent vasoconstrictor, can promote fibroblast differentiation, migration, and survival. Antagonists of endothelin receptors have been explored as potential IPF treatments, but trials have shown mixed results, highlighting the complexity of endothelin’s role. Other pathways that are also important and were described their role in details are: Cyclic Nucleotides and Phosphodiesterases: cAMP and cGMP, second messengers generated by adenylate cyclase and guanylyl cyclase, respectively, are involved in maintaining endothelial barrier integrity and vascular smooth muscle tone. Inhibition of phosphodiesterases (PDEs), enzymes that degrade cAMP and cGMP, has shown promise in preclinical studies. Clinical trials targeting cGMP with drugs like riociguat and sildenafil have produced varied outcomes.

The researchers believe Prostanoids, including prostacyclin (PGI2), have antifibrotic properties and can inhibit fibroblast proliferation, ECM secretion, and myofibroblast phenotype. Prostanoid receptor agonists and inhibitors have been investigated for IPF treatment, with some promising results. They also indicated that RhoA/ROCK signaling, which regulates cell contraction and adhesion, is implicated in IPF. Selective inhibition of ROCK2 has shown potential as a therapeutic approach. According to the authors, aberrant coagulation has been observed in IPF, contributing to fibrin deposition and inflammation. Targeting specific coagulation pathways, such as factor Xa inhibition, holds promise for IPF treatment.

The study by Dr. Gisli Jenkins and colleagues underscores the crucial role of endothelial dysfunction in the pathogenesis of IPF. The interaction between endothelial cells, vascular smooth muscle cells, and other cell types contributes to fibrosis and vascular remodeling. Understanding these molecular mechanisms offers the potential for novel therapeutic targets. Several clinical trials have explored drugs targeting these pathways, with varying degrees of success. While some trials have not met their primary endpoints, others have shown promising results in secondary endpoints, such as improved lung function or quality of life. The complexity of IPF’s pathogenesis highlights the need for a multifaceted approach to treatment.

The Role of Endothelial Dysfunction in Idiopathic Pulmonary Fibrosis: A Pathway to Novel Therapeutic Approaches - Medicine Innovates

About the author

Professor Gisli Jenkins
Faculty of Medicine, National Heart & Lung Institute
Imperial College London

Gisli Jenkins is a respiratory physician and cell & molecular biologist studying how the lung responds to injury to understand what drives progressive pulmonary fibrosis rather healing, repair and regeneration. He is an NIHR Research Professor, he leads the Margaret Turner Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute and is an honorary consultant physician at the Royal Brompton Hospital, London.

About the author

Professor Jane Mitchell
Faculty of Medicine, National Heart & Lung Institute
Imperial College London

Jane Mitchell is Head of the Vascular Biology research group at NHLI. Professor Mitchell is a stream lead for the taught MSc course: Genes, Drugs and Stem Cells.

Professor Mitchell completed a PhD in Pharmacology with Sir Professor John R Vane (FRS, Nobel Laureate) and Dr Gilberto De Nucci 1990 before joining Professor Ferid Murad (NAS USA, Nobel Laureate) as a fellow of Northwestern University (Chicago, USA) for her postdoctoral training in the biochemistry of nitric oxide synthase. She returned to work with John Vane on the pharmacology of cyclo-oxygenase isoforms before joining the group of Professor Timothy Williams at the National Heart and Lung Institute, now part of Imperial College.

Professor Mitchell was awarded a Wellcome Trust Career Development Fellowship in 1997 and the Novartis Prize for Pharmacology in 1999 for her contribution to the field of cyclo-oxygeanse biology. Since this time, Professor Mitchell has led her own group – Cardiothoracic Pharmacology – consisting of academics, clinicians, postdoctoral fellows and undergraduate/postgraduate students.

Professor Mitchell is amongst the top 1% of cited pharmacologists world-wide and as such, is a member of Thomson Scientific Highly cited listings ( with more than 150 publications in peer reviewed journals.

Professor Mitchell was awarded the AstraZeneca Women in Pharmacology Prize in 2012


May J, Mitchell JA, Jenkins RG. Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis. J Clin Invest. 2023 ;133(18):e172058. doi: 10.1172/JCI172058.

Go To J Clin Invest.